# Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

> **NCT02893488** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 20 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** DTG/ABC/3TC FDC DISPERSIBLE TABLET
- **DRUG:** EPZICOM (ABC/3TC)
- **DRUG:** TIVICAY (DTG)

## Key facts

- **NCT ID:** NCT02893488
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2016-11-01
- **Final completion:** 2016-11-25
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02893488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02893488, "Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02893488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*